| ★ |  Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | |
| 3 |  IgG4-related disease (IgG4-RD): update on diagnosis and treatments in 2025 | | 1.3K | — | 80 |
| 13 |  From basics to updates for cutaneous lupus erythematosus (CLE) | | 1.1K | — | 73 |
| 12 |  Recent advances in the treatment of inflammatory myopathies | | 618 | — | 74 |
| 5 |  Steroids in Relapsing Polychondritis | | 474 | — | 76 |
| 9 |  How to find hidden Antiphospholipid Syndrome (APS) | | 471 | — | 74 |
| 2 |  What is the added value of triple therapy in lupus nephritis? | | 438 | — | 81 |
| 7 |  Quality of life in Relapsing Polychondritis (RP) | | 412 | — | 75 |
| 4 |  Why morning joint stiffness and swelling in rheumatic diseases? | | 398 | — | 76 |
| 11 |  Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 74 |
| 14 |  Treatment of systemic sclerosis-associated interstitial lung disease: where do we stand in 2025? | | 285 | — | 73 |
| 17 |  2026 focus on monogenic Ehlers-Danlos syndromes: periodontal and vascular variants | | 267 | — | 72 |
| 8 |  Exercise as a non-pharmacological treatment adjunct to pharmacotherapy in systemic sclerosis. | | 222 | — | 75 |
| 18 |  The Path to Better Treatments: A Patient-Friendly Guide to Sjögren’s Clinical Trials | | 171 | — | 72 |
| 1 |  Unconventional therapies in connective tissue diseases | | 110 | — | 81 |
| 15 |  Vaccination in undifferentiated connective tissue disease (UCTD) | | 103 | — | 73 |
| 16 |  Osteoporosis in rare and complex connective tissue diseases | | 96 | — | 73 |
| 6 |  Unmet Needs in Childhood-Onset Sjögren's Disease – Patient and Clinician Perspectives | | 82 | — | 76 |
| 10 |  “Doctor, can you ask me…?” for connective tissue diseases patients | | 46 | — | 74 |
| 20 |  Genetic Testing in the Era of NGS: Lessons from the Hereditary Connective Tissue Disorders | | 35 | — | 72 |
| 19 |  Evaluating the quality of the Global Human Settlement Layer R2023A | International Society for Digital Earth @isde_digitalearth | 33 | — | 72 |